Compounds > n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea
Page last updated: 2024-12-07

n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID128803
CHEMBL ID1998062
SCHEMBL ID3366352
MeSH IDM0182978

Synonyms (22)

Synonym
nsc-624548
nsc624548
benzamide, n-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3- chlorophenyl]amino]carbonyl]-2-nitro-
n-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide
n-[[4-(5-bromopyrimidin-2-yl)oxy-3-chloro-phenyl]carbamoyl]-2-nitro-benzamide
benzamide, n-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3-chlorophenyl]amino]carbonyl]-2-nitro-
NCI60_007454
ho-221
NEURO_000252 ,
SCHEMBL3366352
n-[[4-(5-bromopyrimidin-2-yl)oxy-3-chlorophenyl]carbamoyl]-2-nitrobenzamide
n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n'-(2-nitrobenzoyl)urea
ho 221
105128-93-6
benzamide, n-(((4-((5-bromo-2-pyrimidinyl)oxy)-3-chlorophenyl)amino)carbonyl)-2-nitro-
WKXWMGOTZJGIIK-UHFFFAOYSA-N ,
n-(2-nitrobenzoyl)-n'-[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]urea
CHEMBL1998062
DTXSID20146979
benzamide, n-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3-chlorophenyl]amino]carbonyl]-2-nitro-;benzamide, n-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3-chlorophenyl]amino]carbonyl]-2-nitro-
n-(4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl)-n/'-(2-nitrobenzoyl)urea
n-((4-((5-bromopyrimidin-2-yl)oxy)-3-chlorophenyl)carbamoyl)-2-nitrobenzamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" However, HO-221 exhibits extremely poor bioavailability after oral administration because it is only slightly soluble in water (0."( Pharmacokinetics of a micronized, poorly water-soluble drug, HO-221, in experimental animals.
Iwao, T; Kikuchi, M; Kondo, N; Ogyu, S; Ohyama, K; Shu, H; Yamanouchi, K; Yokoyama, K, 1993)		0.29

Dosage Studied

ExcerptRelevanceReference
" A solid dosage form could also be made from that suspension with addition of sucrose palmitate which prevented aggregation caused by the hydrophobic interaction."( Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region.
Haga, T; Ishihara, Y; Iwao, T; Kondo, N; Masuda, H; Ogawa, Y; Yamada, N; Yamanouchi, K; Yokoyama, K, 1993)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's12 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.88 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		2.3820mitomycinalkylating agent;
antineoplastic agent
etoposide
[no description available]		1.9710beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Abnormalities, Autosome
[description not available]		01.9810
Leukemia L 1210
[description not available]		02.6730
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710
Experimental Leukemia
[description not available]		02.3820
Experimental Neoplasms
[description not available]		02.3820
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9710
Breast Cancer
[description not available]		01.9710
Cancer of Pancreas
[description not available]		02.3820
Cancer of Stomach
[description not available]		02.3820
Colorectal Cancer
[description not available]		01.9710
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9710
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		02.3820
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.3820
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		01.9710